Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1089]

Novel therapies in mCRPC: Tarlatamab targeting DLL3 shows early activity in...

Dr Rahul Aggarwal - University of California, San Francisco, USA

Novel therapies in mCRPC: Tarlatamab targeting DLL3 shows early activity in neuroendocrine mCRPC ( Dr Rahul Aggarwal - University of California, San Francisco, USA )

Highlights from APCCC 2026

Dr Natalia Gandur - Instituto de Oncología 'Ángel H. Roffo', Buenos Aires...

Highlights from APCCC 2026 ( Dr Natalia Gandur - Instituto de Oncología 'Ángel H. Roffo', Buenos Aires, Argentina )

ASCO 2026: Updates in bladder cancer

Dr Natalia Gandur - Instituto de Oncología 'Ángel H. Roffo', Buenos Aires...

ASCO 2026: Updates in bladder cancer ( Dr Natalia Gandur - Instituto de Oncología 'Ángel H. Roffo', Buenos Aires, Argentina )

ASCO 2026: Updates in renal cancer

Dr Natalia Gandur - Instituto de Oncología 'Ángel H. Roffo', Buenos Aires...

ASCO 2026: Updates in renal cancer ( Dr Natalia Gandur - Instituto de Oncología 'Ángel H. Roffo', Buenos Aires, Argentina )

ASCO 2026: Updates in testicular, germ cell and rare genitourinary cancer

Dr Natalia Gandur - Instituto de Oncología 'Ángel H. Roffo', Buenos Aires...

ASCO 2026: Updates in testicular, germ cell and rare genitourinary cancer ( Dr Natalia Gandur - Instituto de Oncología 'Ángel H. Roffo', Buenos Aires, Argentina )

Understanding patient expectations and clinicians' goals in favourable risk...

Prof Daniele Santini and Dr Yann Alexandre Vano

Understanding patient expectations and clinicians' goals in favourable risk aRCC patients ( Prof Daniele Santini and Dr Yann Alexandre Vano )

Talazoparib plus enzalutamide improves radiographic progression-free survival...

Dr Neeraj Agarwal - University of Utah, Salt Lake City, USA

Talazoparib plus enzalutamide improves radiographic progression-free survival in HRR-altered mCSPC ( Dr Neeraj Agarwal - University of Utah, Salt Lake City, USA )

ASCO 2026: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ASCO 2026: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

ASCO 2026: Latest in prostate cancer

Prof Eleni Efstathiou, Prof Boris Hadaschik, Dr Mary-Ellen Taplin and Prof Axel...

ASCO 2026: Latest in prostate cancer ( Prof Eleni Efstathiou, Prof Boris Hadaschik, Dr Mary-Ellen Taplin and Prof Axel Merseburger )

177Lu-rosopatamab plus standard of care shows manageable safety and favourable...

Dr Pedro Barata - University Hospitals Seidman Cancer Center, Cleveland, USA

177Lu-rosopatamab plus standard of care shows manageable safety and favourable tumour targeting in mCRPC ( Dr Pedro Barata - University Hospitals Seidman Cancer Center, Cleveland, USA )

Xaluritamig plus abiraterone shows promising anti-tumour activity with...

Dr David Pook - Monash Health, Melbourne, Australia

Xaluritamig plus abiraterone shows promising anti-tumour activity with manageable safety in chemotherapy-naïve mCRPC ( Dr David Pook - Monash Health, Melbourne, Australia )

miR371 shows promise as a surveillance biomarker for relapse in early-stage...

Dr Lucia Nappi - University of British Columbia, Vancouver, Canada

miR371 shows promise as a surveillance biomarker for relapse in early-stage germ cell tumours ( Dr Lucia Nappi - University of British Columbia, Vancouver, Canada )

More from ecancer